- Home
- CRIS
CRIS
Curis Inc.
as 12-18-2024 2:34pm EST
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 31.2M | IPO Year: | 2000 |
| Target Price: | $23.00 | AVG Volume (30 days): | 66.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.43 - $17.49 | Next Earning Date: | 02-06-2025 |
| Revenue: | $10,259,000 | Revenue Growth: | 0.44% |
| Revenue Growth (this year): | -1.84% | Revenue Growth (next year): | -16.04% |
Latest Curis Inc. News
CRIS Breaking Stock News: Dive into CRIS Ticker-Specific Updates for Smart Investing
PR Newswire
8 days ago
Curis Announces Additional Data from TakeAim Leukemia Study
Simply Wall St.
a month ago
Curis Third Quarter 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
a month ago
Q3 2024 Curis Inc Earnings Call
GuruFocus.com
a month ago
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...
Zacks
a month ago
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
a month ago
Curis: Q3 Earnings Snapshot
PR Newswire
a month ago
Curis Provides Third Quarter 2024 Business Update
GuruFocus.com
a month ago
Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of Earnings
Compare CRIS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRIS Curis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.